• Herling AW et al. Agents Actions. 1987 Feb;20(1-2)
• Bradshaw, J., et al.: Brit. J. Pharmacol., 66, 464 (1979)
• Berstad, A., et al.: Scand. J. Gastroenterol, 15, 637 (1979)
• Hohnjec, M., et al.: Anal. Profiles Drug Subs., 15, 533 (1979)
• Spurling, N.W. et al., Hum. Toxicol., 1989, 8, 23, (chronic tox)
• Kojic-Prodic, B. et al., Acta Cryst. B, 1982, 38, 1837, (cryst struct)
• Wormsley, K.G., Drugs, 1993, 46, 976, (tox, rev)
• Brogden, R.N. et al., Drugs, 1982, 24, 267, (rev, pharmacol)
• Misiewicz, J.J. et al., Curr. Clin. Pract. Ser., 1984, 15, (book)
• Hohnjec, M. et al., Anal. Profiles Drug Subst., 1986, 15, 533, (rev, synth, anal, metab)
• Cholerton, T.J. et al., J.C.S. Perkin 2, 1984, 1761, (uv, ir, pmr, struct)
• The Landmark Papers: The H2-Receptor Antagonists, (Ed. Pounder, R.E.), Science Press, 1990, (pharmacol, book)
• Daly, M.J. et al., Prog. Med. Chem., 1983, 20, 337, (rev, pharmacol)
• Daly, M.J. et al., Br. J. Pharmacol., 1981, 72, 49; 55, (pharmacol)
• Riley, A.J. et al., Curr. Clin. Pract. Ser., (Eds.), No. 1: Ranitidine, Excerpta Medica, Amsterdam, 1982, (book)
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, RBF400
• Grant, S.M. et al., Drugs, 1989, 37, 801, (pharmacol, rev)
• Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 1209; 1211
• Ger. Pat., 1978, Allen and Hanburys, 2 734 070; CA, 88, 190580b, (synth, pharmacol)
• Gaginella, T.S. et al., Drug Intell. Clin. Pharm., 1983, 17, 873, (rev, pharmacol)
• Negwer, M., Organic-Chemical Drugs and their Synonyms, 6th edn., Akademie-Verlag, 1987, 2946
• Bradshaw, J., Chron. Drug Discovery, 1993, 3, 45, (rev)
• Geraldes, C.F. et al., Magn. Reson. Chem., 1987, 25, 203, (pmr, cmr)
• Kirch, W., Pharmacol. Ther., 1987, 33, 129, (rev)
